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Hilights:   
Compartmentalized dynamics of cytomegalovirus replication in treated congenital 
infection 
x Virus was only detectable in the blood at baseline in 15/17 babies, but in all urine 
and saliva specimens, despite all babies having evidence of CMV disease. 
x The median half-life (T1/2) of virus decline in blood of 2.4 days (IQR 1.9-3.3) is similar 
to that observed in immunocompromised adults. 
x Given the similar T1/2 in adults and neonates during early stages of treatment it is 
unclear why nearly 2/3 of babies continue to have CMV DNA detectable at the end 
of a 6 week treatment course. 
x Virus dynamics differ between blood and urine which may have significance for 
future studies in this age group. 
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ABSTRACT 1 
Background:  Cytomegalovirus (CMV) is the most prevalent congenital infection in 2 
developed countries.  A significant number of infected infants develop long-term 3 
neurodevelopmental and hearing impairment irrespective of whether disease is detectable 4 
at birth.  Studies of viral load and replication dynamics have informed the treatment of CMV 5 
in adult populations but no similar data exist in neonates.     6 
Objectives:  To study CMV virus kinetics in different body fluids of babies treated for 7 
congenital infection. 8 
Study design:  CMV virus load was sequentially analyzed in blood, urine and saliva in 17 9 
babies treated for symptomatic congenital CMV infection. 10 
Results:  Virus was detectable in the urine and saliva of all babies at baseline but in only 11 
15/17 in blood.  At the end of 6 weeks of antiviral treatment CMV remained detectable in 12 
9/14 blood samples, 9/12 urine samples and 4/7 salivary swabs.  Median half-life (T1/2) of 13 
virus decline in blood was 2.4 days (IQR 1.9-3.3) and basic reproductive number (Ro) was 14 
2.3.  Although T1/2 values were similar in urine and saliva to those observed in blood, virus 15 
dynamics differed both during and after treatment.   16 
Conclusions:  T1/2 and Ro in blood in this group of neonates were similar to values derived 17 
from studies of immunocompromised adults.  The persistent viremia observed in treated 18 
neonates cannot therefore be adequately explained by the virus dynamics early in 19 
treatment.  The different dynamics exhibited in blood and urine suggests that studying 20 
changes in distinct body compartments may assist in further understanding long-term 21 
manifestations of disease.   22 
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BACKGROUND 24 
Cytomegalovirus (CMV) is a common congenital infection and an important cause of 25 
sensorineural hearing loss (SNHL) [1, 2].  A minority of those infected will have clinically 26 
detectable disease at birth, but 13% of those without disease will subsequently develop 27 
significant impairments, particularly SNHL [3].   28 
Antiviral treatment improves hearing and neurodevelopmental outcomes when started in 29 
the first month of life in symptomatic newborns [4, 5].  There are no randomized studies to 30 
support treatment of babies without detectable disease at birth and the search for 31 
prognostic markers for adverse long term outcome in these newborns is ongoing .  32 
Natural history studies in adult transplant recipients show that high viral load and viral 33 
kinetics in whole blood correlate with the development of CMV end-organ disease [6] with 34 
viruria independently associated with disease in renal transplant patients. 35 
High viral load has also been associated with poor long-term outcomes in congenitally 36 
infected babies in some studies [7-11] but not others [12].   A major limitation is the lack of 37 
adequate numbers of babies without disease at birth that subsequently develop CMV-38 
related morbidity.  As SNHL is progressive, the duration of follow-up required to produce 39 
meaningful results further impacts on the conduct of such studies [13].   40 
Data in infants largely reports single measurements of viral load rather than sequential 41 
monitoring coupled with viral kinetic modelling.  A recent study in neonates treated for 42 
congenital CMV (CCMV) observed a correlation between higher burden of CMV DNA in the 43 
blood in the first 6 weeks of treatment and subsequent SNHL [5].  Given the known 44 
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prolonged urinary excretion of CMV in those infected in early life it is possible that virus 45 
kinetics differ between body fluids in this group, but no data exist currently.    46 
Further defining the natural history of CMV virus kinetics in different body fluids in those 47 
with CCMV could aid our understanding of the pathogenesis of this virus and assist in 48 
developing biomarkers. 49 
OBJECTIVES 50 
This study aimed to define the kinetics of CMV replication in blood, urine and saliva in a 51 
group of babies receiving treatment. 52 
STUDY DESIGN  53 
The Viral load and Immunology in Congenital CMV (VICC) study recruited babies into an 54 
ethically approved protocol in the UK.  19 babies with CCMV were recruited from 7 study 55 
sites between 2008 and 2011.   After CCMV diagnosis, participants in the study provided 56 
blood, urine and salivary samples at set time-points during and after treatment and up to 57 
two years of age.  CMV quantitative analysis was performed in the Department of Virology 58 
at the Royal Free Hospital.  Only the 11 babies that received treatment, with sufficient viral 59 
load results for meaningful analysis, are presented here (see supplemental data). 60 
An ethically approved treatment registry for CCMV was also active in the UK during the 61 
same time period.  Babies in this registry with multiple entries for CMV viral load were 62 
included for analysis (N=2)(see supplemental data).  The parent(s) or legal guardian(s) of 63 
participants in both the above studies provided written informed consent.   64 
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Multiple samples were also received at our laboratory from 3 treated babies as part of 65 
routine clinical care.     66 
Definitions:   67 
 CCMV was confirmed if a sample tested positive for CMV within 21 days of life.  68 
Symptomatic infection was defined according to criteria used in a previously published 69 
randomised controlled trial (RCT) of treatment [4].   70 
Salivary swab acquisition: 71 
Salivary samples were taken using neonatal flocked swabs (Sterilin™ Cambridge, UK) at least 72 
one hour after the baby’s last feed.  Swabs were resuspended in 1ml virus transport 73 
medium (VTM) prior to extraction.    74 
Detection and quantitation of CMV DNA:  75 
 Total nucleic acid was extracted using the commercial Nuclisense Easymag system 76 
(Biomerieux, Basingstoke UK) according to manufacturer’s instructions.  CMV viral load was 77 
then determined using an in-house real-time quantitative PCR as described previously   78 
(lower limit of detection being 200 copies/ml, (168 IU/ml)).  [14].     79 
An estimate of the volume of saliva held on swabs was obtained by weighing swabs pre- and 80 
post- saturation in saliva.    The mean of 3 samples gave an estimated volume of 27ul of 81 
saliva which allowed for calculations of  CMV viral load/ml of saliva.    82 
 83 
Measurement of ganciclovir levels:  84 
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Ganciclovir (GCV) levels were determined by the Bristol Antimicrobial reference laboratory 85 
as described in detail elsewhere [15].   86 
Statistical analysis: 87 
‘Baseline’ samples were included if they had been obtained before, or within 7 days of, 88 
treatment commencing.  If multiple samples had been obtained prior to treatment the 89 
sample taken closest to treatment onset was used.  End of treatment samples were 90 
accepted if taken +/- 3 days from the last day of treatment.  For analyses involving 91 
comparison of virus load between different body fluids samples were only considered if 92 
taken within one day of each other.     93 
Viral load measurements of <200 copies/ml were entered as half the limit of detection to 94 
enable log conversion and construction of virus decline curves.  Mann-Whitney U test was 95 
used to compare median values, with Wilcoxon signed rank test used for comparison of 96 
paired samples.  97 
Virus decline was calculated using methodology described previously [16].  The slope of 98 
decline of loge (ln) viral load was computed using segmental regression in GraphPad Prism 99 
(GraphPad Software, La Jolla, CA) with X0 constraint for decline set at the point where the 100 
phase of most rapid viral decline appeared to end.  Virus half-life was then defined using the 101 
formula (-ln2)/slope. 102 
For the calculation of the basic reproductive number (Ro) after cessation of therapy the 103 
following formula was used: 104 
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Ro = 1+ r/G ert  where r is the growth rate of virus after stopping therapy, G Is the death rate 105 
of a CMV infected cell (taken from Emery et al, 1999) and t is a time delay between infection 106 
and production of new virions (set at 2 days)[16]. 107 
RESULTS 108 
Participants: 109 
The study included viral load data from 17 babies treated for congenital CMV.   All babies 110 
had clinical signs or symptoms of congenital infection with central nervous system (CNS) 111 
involvement.  SNHL was the only evidence of suspected CNS disease in one neonate.   112 
Treatment was with intravenous ganciclovir (iv GCV) at a dose of 5-6mg/kg twice daily (bid) 113 
(n=10), oral valganciclovir (VGCV) at a dose of 10-17mg/kg bid alone (n=2) or a combination 114 
of iv GCV followed by VGCV (n=5).  All babies receiving mixed treatment commenced with iv 115 
GCV for a minimum of 6 days.   116 
Baseline viral loads: 117 
In blood and urine samples 13/17 and 14/15 were taken prior to, or on the day of, 118 
treatment initiation.  In saliva 6/8 baseline specimens were acquired after day 0 of 119 
treatment (median 3 days).     120 
DNAemia was detected in 15/17 (88%) neonates at baseline. All urine and saliva samples 121 
were CMV DNA positive.  Both the neonates with undetectable DNAemia had samples taken 122 
prior to treatment commencing.  Median and interquartile ranges (IQR) of CMV loads at 123 
baseline in blood, urine and saliva were 3.8 (3.3-4.2), 7.7 (7.0-8.4) and 7.2 (6.8-8.3) log10 124 
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genomes/ml with corresponding means of 3.8 (SD ± 0.8), 7.7 (± 0.9) and 7.3 (± 1.5) (Figures 125 
1 and 2). 126 
More than one blood sample and more than one urine sample were taken in five neonates 127 
before treatment.  In 2/5 of these babies viral load in blood and urine decreased by more 128 
than 1.0 log10 genomes/ml (blood:  range 0.2-1.5 log10  genomes/ml over 6-21 days; urine:  129 
range 0.1-1.6 log10  genomes/ml over a period of 1-23 days).   130 
End of treatment viral load: 131 
At the end of a 42 day treatment course CMV remained detectable in 9/14 blood samples 132 
(65%), 9/12 urine samples (75%) and 4/7 salivary swabs (57%).  Median CMV load in blood, 133 
urine and saliva in babies with virus still detectable was 2.8 log10 genomes/ml (IQR 2.5-3.5), 134 
2.9 log10 genomes/ml (IQR 2.7-3.9) and 4.0 log10 genomes/ml (IQR 3.2-5.5) respectively.  135 
CMV loads were significantly lower at the end of treatment in blood and urine, but not 136 
saliva, compared to baseline values (P = <0.01, 0.02 and 0.13 respectively).   137 
CMV kinetics during therapy:  138 
Baseline CMV loads were approximately 4.0 log10 genomes/ml higher at the start of 139 
treatment in urine and saliva as compared with blood but this difference narrowed during 140 
the 42 days of treatment (Figure 1).  In keeping with this observation, viral decline between 141 
the start and end of 42 days treatment was higher in urine and saliva compared to blood 142 
with an absolute decline of -1.2 log10 genomes/ml (IQR -1.8 to -0.9) observed in 14 paired 143 
blood samples compared to -4.4 log10 genomes/ml (IQR -5.5 to -3.8) in urine (N=10) and -4.8 144 
log10 genomes/ml (IQR -5.2 to -3.9) in saliva (N=7)(Table 1).  In 2/14 paired blood samples no 145 
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decline was observed during treatment whereas CMV DNA decreased in all urine and 146 
salivary samples. 147 
CMV DNA decline in blood and urine was more rapid during the first 7 days of treatment 148 
when compared to the full 42 days of treatment (Table 1).  Salivary samples from early 149 
sampling points were too few to allow for analysis.   150 
Using these data, the half-life of decline (T1/2) was calculated using segmental regression of 151 
the most rapid phase of virus decline (examples shown in Figure 3).  The median T1/2 in 152 
blood of 14 neonates was 2.4 days (IQR 1.9-3.3 days), in urine it was 2.0 days (IQR 1.3-2.6) 153 
(N=14) and in saliva 1.5 days (IQR 1.4-2.4) (N=4).   154 
Post therapy kinetics:  155 
Once treatment had stopped, a rebound of CMV DNA levels was observed within 1 week in 156 
4/8 blood, 6/9 urine and 1/5 saliva samples.  The median increase in CMV load over the first 157 
7 days post-treatment was 0.52 (blood), 1.04 (urine) and 2.05 (saliva) log10 genomes/ml 158 
(Figure 2).  Where no rebound was observed virus had been undetectable at the end of 159 
treatment in 2/4 (blood), 1/3 (urine) and 2/4 (saliva) babies; in the remaining babies virus 160 
was still detectable but continued to decrease after treatment discontinuation. 161 
Maximum virus levels following treatment were at age 3 months in blood and age 6 months 162 
in urine and saliva samples (Figure 2).  Median maximum virus load was not significantly 163 
different from baseline in blood (3.78 vs 2.96 log10 genomes/ml respectively; P=0.3) or saliva 164 
(7.39 vs 7.16 log10 genomes/ml respectively; P = 0.72).  Urine CMV load was, however, 165 
significantly lower at 6 months of age compared to baseline (median 5.94 vs 7.74 log10 166 
genomes/ml respectively; P= <0.01).  167 
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The basic reproductive number (Ro) was calculated using the growth rate derived from the 168 
post therapy virus rebound and previous estimates of the death rate of a CMV infected cell 169 
in vivo (~0.98 day).  This calculation revealed a median Ro value of CMV in blood of 2.3 (n=2) 170 
in urine of 2.8 (n=2) and in saliva of 4.6 (n=1).  171 
Long-term viral control: 172 
CMV DNA remained detectable in no blood samples (n=6) at month 12 but in most urine 173 
(7/7) and saliva (6/8) samples.  By 24 months CMV DNA remained undetectable in all blood 174 
samples (n=3) but was detectable in 2/3 urine and 1/3 saliva samples.  In urine the median 175 
CMV load at 12 months was 4.7 log10 genomes/ml (IQR 4.5-5.8)(N=7) which was significantly 176 
lower than the baseline load  (7.7 log10 genomes/ml (p<0.01)).  Similarly, salivary viral load 177 
was significantly lower at month 12 than at baseline [4.5 log10 (IQR 2.5- 5.1) vs 7.56 log10 178 
(IQR 6.76-8.44) genomes/ml respectively (p <0.01)]. 179 
Ganciclovir levels: 180 
Ganciclovir levels were mostly below quoted reference values of 0.5 mg/L (trough) and 181 
7.0mg/L (peak) (Figure 4).  Plotting log10 virus decline during the first 7 days of treatment 182 
against peak and trough GCV levels at day 7 did not reveal any significant association 183 
between these two parameters in the 5 babies studied (supplemental data).    184 
DISCUSSION 185 
The results of this study provide insight into the kinetics of CMV in different biological 186 
compartments in neonates during and after antiviral therapy.  Despite the differences in 187 
baseline CMV load, half-lives during the initial phase of treatment were comparable across 188 
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compartments (P = 0.1-0.4 for inter-group comparisons) and similar to the 2 days observed 189 
in infrequently sampled adult immunocompromised hosts [16].   190 
In contrast to data from studies in adult transplant patients with similar starting virus loads 191 
over half of the neonates still had DNAemia detectable at the end of the 6 week treatment 192 
course [14].  This observation and that of an initially rapid virus decline followed by a nadir 193 
is in keeping with similar observations in treated neonates [17].   194 
The reasons for this incomplete suppression in neonates are unclear.  In the setting of CMV 195 
replication in HIV infection the efficacy of iv GCV (5mg/kg/bid) has been estimated at 91.5% 196 
[18] but where plasma levels are lower the efficacy will be reduced.  Therapeutic drug 197 
monitoring of GCV levels in the neonates enrolled in this study indicate that plasma GCV 198 
levels were low but consistent with other data in children [15].  Higher levels of GCV may be 199 
needed in this population to fully inhibit replication.  Analysis of the CMV UL97 locus 200 
showed no evidence of mutations known to confer GCV resistance.  201 
Alternatively, persistent viremia may represent continued virus excretion from ‘sanctuary 202 
sites’ inaccessible to antiviral agents.  Given the increased audiological and neurological 203 
morbidity observed in CCMV when compared to immunocompromised adults, the inner ear 204 
or CNS would be possible sources of such virus reservoirs and drug penetration at these 205 
sites correspondingly suboptimal [19].  Testing such a hypothesis is challenging since no 206 
data evaluating virus persistence in CSF exist, nor is this likely to be ethically acceptable. 207 
Although rebound of virus was common in all body fluids in the first week post-treatment, 208 
maximal rebound occurred earlier in blood when compared to urine and saliva; the rebound 209 
in DNA-emia is consistent with other recent reports during neonatal treatment [5].  Only 210 
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virus in urine rebounded to a level significantly lower than baseline in our study.  This is an  211 
important observation if the ‘threshold’ concept of CMV disease proposed in adults applies 212 
to CCMV [20].   213 
If virus is not in a steady state at the initiation of therapy then the dynamic models adopted 214 
may not be fully applicable.  However, congenital infection often occurs months before birth 215 
and the values obtained here are consistent with those derived in adults.  The growth of 216 
CMV during the rebound phase allowed us to estimate Ro for CMV during this resurgence in 217 
replication.  The Ro values are relatively modest at 2.3 and 2.8 for blood and urine 218 
respectively, consistent with those observed in D+R- solid organ transplant recipients [21].      219 
Overall the data presented here imply that initial viral response to treatment is similar to 220 
that observed in adult immunocompromised hosts.  However, following this initial response, 221 
CMV replication patterns differ in neonates when compared to immunocompromised 222 
adults.  In keeping with this altered virus kinetics is the ongoing audiological damage and 223 
neurological damage unique to this age group.  The reasons for this remain to be elucidated 224 
but are likely a complex combination of host and virus factors, including immunological 225 
immaturity and a possible increased susceptibility of the rapidly dividing cells in early life to 226 
viral damage.    227 
It is possible that even longer periods of treatment or antiviral drugs with better CNS 228 
penetration will be needed if the continued detection of high amounts of virus in urine is of 229 
relevance for subsequent neurological outcomes. The challenge must now be to evaluate 230 
whether current antiviral agents reach the body compartments relevant for disease at 231 
sufficient levels to prevent viral replication and/or damage and whether monitoring virus 232 
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load in multiple body compartments can assist in further defining viral parameters of 233 
importance for future prognosis.       234 
WORD COUNT 2536 235 
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 237 
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Table 1:  Median viral decline in different body fluids over time in 17 babies treated for 
congenital CMV. 
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Figure 1  
Mean viral load over time in different body fluids in 17 babies treated for congenital 
cytomegalovirus.  
 CMV viral load was measured in blood, urine and saliva using quantitative real-time PCR.   
Treatment was with either ganciclovir or valganciclovir in all babies and for a duration of 42 
days +/- 1 day in 16/17 babies.   
 
Figure 2 
CMV virus load over time in different body compartments in 17 babies treated for 
congenital CMV 
Quantitative CMV viral load measured in (A) blood, (B) urine and (C) saliva at different time 
points during and after treatment. 
Baseline = start of treatment; End treatment = end of treatment course; D3 and D7 Post = 3 
and 7 days after treatment discontinued respectively; M3, 6, 12 = age 3, 6 and 12 months of 
life respectively. 
Error bars represent median and interquartile range.  
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Figure 3: Example of segmental regression of loge blood viral load in 6 babies treated over 
42 days for congenital cytomegalovirus. 
Plots were constructed using GraphPad Prism software to define 2 phases of virus decline.  
Examples are shown for 6 babies.  Plots in the remaining 8 babies and in other body fluids 
were constructed in a similar way. 
 
Figure 4: Pre- (A) and Post- (B) dose ganciclovir levels in babies treated for congenital CMV 
Ganciclovir (GCV) levels measured in babies aged <6 months of age (<6mo) and <28 days of 
age (<28 days) being treated for congenital CMV.  Levels are compared between those 
derived from anonymized data received from the British Antimicrobial reference laboratory 
and described in detail elsewhere (Luck et al IJAA 2011 [15]) and  those obtained during the 
viral load and immunology in congenital CMV (VICC) study. 
Supplemental data:  Relationship between virus decline in blood (A. and B.) and urine (C. 
and D.) and ganciclovir levels over the first 7 days of antiviral treatment for congenital 
cytomegalovirus infection. 
Data are shown for day 7 pre- (trough: B. and D.) and post- (peak: A. and C.) ganciclovir 
levels taken on day 7 of treatment in 5 babies.  Treatment was with ganciclovir in 4 and 
valganciclovir in 1 baby.   
 
Supplemental data: Viral load at each time point in different body fluids in 17 babies 
treated for congenital cytomegalovirus (CMV) 
Table 1:  Median viral decline in different body fluids over time in 17 babies treated for 
congenital CMV. 
 
Body fluid Time points compared 
 D0-D42 viral decline  
(IQR) 
D0-3 viral decline 
(IQR) 
D0-7 viral decline  
(IQR) 
Blood 0.03 (0.04-0.02)  
N=12 
0.3 (0.5-0.1)  
N= 2 
0.12 (0.16-0.10) 
N=12 
Urine 0.10 (0.14-0.08)  
N= 13 
0.63 (0.85-0.38)  
N= 4 
0.21 (0.3-0.07) 
N= 12 
 
Viral decline is represented as log10 copies/day   
D= Day of treatment; N= Number of paired samples available for analysis; IQR = 
Interquartile Range 
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Viral load at each tim
e point in different body fluids in 17 babies treated for congenital cytom
egalovirus (CM
V) 
 
   
Subject num
bers 1-8, 12, 16, 17 w
ere recruited into the VICC study 
Subject num
bers 9-11 w
ere recruited into the CM
V treatm
ent registry 
Subject num
bers 13-15 w
ere sam
ples received from
 clinical cases  
  BLOOD
Day of treatm
ent
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
0
3.79
2.47
4.14
3.33
2.00
2.00
2.89
3.50
5.00
4.26
4.10
4.70
5.07
3.77
2.72
4.00
3.22
35
2.58
2.00
2.00
2.91
3.89
2.00
3.31
2.00
42
2.66
3.29
2.46
2.00
2.00
2.00
2.52
3.62
3.10
2.84
2.32
2.00
4.15
2.00
45
2.63
2.81
3.29
2.00
4.38
49
3.64
2.80
2.00
2.96
2.00
3.45
3.38
4.58
2.00
90
3.81
2.00
3.26
2.00
2.65
5.56
3.88
2.00
Subject num
ber
URINE
Day of treatm
ent
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
0
7.66
7.78
9.55
6.41
7.74
6.72
8.42
8.29
8.5
6.69
8.6
7.57
7.33
7.81
6.12
35
2.71
3.63
3.42
2
4.99
6.3
4.44
4.13
4.84
2
42
2.65
2.84
4
2.87
3.67
2
2.72
5.52
2
2.39
3.89
2
45
2.57
3.16
2
3.1
4.03
49
2.49
3.77
3.58
4.01
3.65
4.52
5.67
4.1
2
90
3.46
3.9
5.81
6.04
4.39
6.23
5.09
8.43
4.39
Subject num
ber
SALIVA
Day of treatm
ent
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
0
8.54
9.61
6.72
6.77
7.01
4.47
7.31
8.20
35
3.43
3.26
42
3.77
2
2
5.94
2
4.25
2.99
45
3.86
2
2
49
4.79
3.28
2
4.05
2
2
90
6.94
6.51
4.59
4.97
2
6.16
6.86
8.36
2
Subject num
ber
Supplem
entary Data
